Clinical Trials Logo

Melanoma Stage III clinical trials

View clinical trials related to Melanoma Stage III.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04675346 Completed - Melanoma Stage III Clinical Trials

Exploring Unmet Needs and Attitudes to Skin Self-examination in Melanoma Survivors

EUNASS
Start date: November 18, 2020
Phase:
Study type: Observational

This is a prospective, multi-centred cohort study whereby the EUNASS Study questionnaire will be administered electronically to identify needs of melanoma survivors, the extent to which these needs are being met, and identify areas which have the greatest need for development. It will also evaluate behaviour in relation to sun protection and skin self-examination (SSE). It will be a self-completed questionnaire. Qualitative work using semi-structured interviews will explore the needs of melanoma survivors in greater depth, will present examples of potential interventions to improve SSE and explore factors that determine the likelihood of engaging in an intervention which can address unmet needs, such as improving SSE. Taken together, the data will provide the evidence base to inform the development of an intervention to improve SSE, which can subsequently be tested in secondary care services.

NCT ID: NCT04154163 Completed - Ovarian Cancer Clinical Trials

Appropriate Dosing to Optimise Personalised Cancer Treatments

ADOPT
Start date: January 10, 2020
Phase:
Study type: Observational

This is a pilot study to assess feasibility of dried blood spot (DBS) samples for pharmacokinetic measurements of targeted anti-cancer drugs in oncology patients such as patients with BRAF-mutant melanoma receiving targeted treatment with BRAF and MEK inhibitors.

NCT ID: NCT03620019 Completed - Melanoma Clinical Trials

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

Start date: September 25, 2018
Phase: Phase 2
Study type: Interventional

This is a multicenter open-label, single-arm, phase II study designed to investigate the pharmacodynamic and antitumor effects of denosumab alone and in combination with an anti-Programmed death-1 or Programmed death ligand 1 (PD1) agent (pembrolizumab or nivolumab) in patients with unresectable Programmed death-1 or Programmed death ligand 1 (PD-1/PD-L1) inhibitor-naïve regional and distant metastatic melanoma (The American Joint Committee on Cancer (AJCC) stage III/IV). The pharmacodynamic and antitumor effects will be investigated by performing translational research on peripheral blood and tumor tissue collected before and during denosumab alone and in combination with anti-PD-1 treatment.

NCT ID: NCT03153085 Completed - Melanoma Stage IV Clinical Trials

A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma

Start date: May 25, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if TBI-1401(HF10) in combination with ipilimumab is effective in Japanese patients with stages IIIB, IIIC, or IV unresectable or metastatic melanoma.